Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 9/20 | 0.79 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948323 | 0.98 | IL4I1 (0.76) | IL4I1HSD17B13EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL30948101 | 0.89 | IL4I1 (0.80) | IL4I1HSD17B13EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL27163390 | 0.89 | IL4I1 (1.00) | IL4I1HSD17B13MAPTSMN1; SMN2HTT | |
| SCHEMBL30948284 | 0.87 | IL4I1 (0.77) | IL4I1HSD17B13EPHX2MAPTSMN1; SMN2 | |
| SCHEMBL30948015 | 0.86 | IL4I1 (0.96) | IL4I1HSD17B13MAPTSMN1; SMN2HTT | |
| SCHEMBL30948142 | 0.83 | IL4I1 (0.74) | IL4I1MAPTSMN1; SMN2HTTCYP11B1 | |
| SCHEMBL30948066 | 0.81 | IL4I1 (0.71) | IL4I1MAPTSMN1; SMN2HTTCYP11B1 | |
| SCHEMBL30948077 | 0.81 | IL4I1 (0.79) | IL4I1HSD17B13GRM5PDE1C | |
| SCHEMBL30948078 | 0.81 | IL4I1 (0.65) | IL4I1CYP11B1CYP11B2PDE1CMAOB | |
| SCHEMBL30948223 | 0.80 | IL4I1 (0.52) | IL4I1HSD17B13EPHX2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885HSD17B13 1546/4885EPHX2 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.